- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
-
Smaller Pharma Wins the 'Most Valuable' Race
-
74 Solid, Growing Companies in a Recession
-
30 Possible Pandemic Profit Plays: Bullish Biotech and Drug Stocks to Watch
-
Aradigm: Hard to Value, But Significant Upside
-
Biotech Opportunities: Look for Decent Pipeline, Big Pharma Partnerships
-
Alkermes Outlook Remains Bleak
-
Wall Street Breakfast: Must-Know News
-
FDA Calendar Updates: Acusphere, AspenBio, Alkermes
-
Who Will Win the Amylin Battle?
-
Early Filing for Byetta: Will It Become a Blockbuster?
-
FDA Calendar Updates: Amylin, Alkermes, Eli Lilly, Cell Therapeutics
-
FDA, Clinical Trial Calendar Updates: Acorda, Alkermes, GTx
-
15 'Bathwater Babies' and 20 'Dogs with Fleas' for the Week
-
Which Diabetes Drugs Will Win Out?
-
Merck's Jumpin' Januvia Gets a Reprieve
-
Monthly Big 5: Stocks Worth Watching
-
Updated FDA Calendar: Cypress Bioscience Looks Like a Buy
-
Eli Lilly's CEO: 'Ludicrous' Stock Price
-
Nine Pharma Predictions for 2009
-
Wall Street Breakfast: Must-Know News
-
Recessionary Equity Strategies: Still Going for Growth
-
Tuesday Options Update: ADM, KGC, AMLN, ALKS, SOLF, HLF & EXPD
-
Why I'm Buying Amylin Now
-
So Much for the Summer Doldrums with Drugmakers
-
BioMarin, Myriad, and Regeneron Show a Quiet Strength
-
Is Lilly and Amylin's Byetta Better?
-
Analyst Notes: Lilly Gets A Lift, Pfizer Goes Pfft
-
Biotech Sector Continues to Outperform
-
Wall Street Breakfast: Must-Know News
-
Generex Biotechnology: Oral-lyn Buccal Insulin Takes Center Stage
-
Inhaled Insulin: Eli Lilly On Its 'Last Breath'?
-
Alkermes Should Profit From Lilly's Delayed Drug
-
Alkermes, Lilly, Mannkind: Inhaled Insulin Just Got Interesting
-
Eat It, Breathe It, Soak in It? Drug Administration Gets Tricky
-
Did Inside Connections Influence Glaxo's Bid For Reliant?
-
Is A New Blockbuster Drug In The Works For Alkermes?
-
Loeb's Third Point Releases 13F Filing, Shows a Number of New Positions
-
Biotech In Review: Dyax Jumps On Positive Data
-
Biotech Day In Review: Roche Picks Up Antibody Firm For $56.5 Million
-
Biotech Day in Review: Novartis Gets Approval for Hypertensive Drug Tekturna
-
Biotech Stocks Review: Seattle Genetics Sells Cancer Drug To Genentech